3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
52
Neoplasms
28
Neoplasm Metastasis
26
Colorectal Neoplasms
26
Recurrence
22
Ovarian Neoplasms
22
Pancreatic Neoplasms
21
Prostatic Neoplasms
20
Breast Neoplasms
20
Squamous Cell Carcinoma of Head and Neck
19
Melanoma
18
Glioblastoma
16
Lymphoma, Large B-Cell, Diffuse
14
Lung Neoplasms
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Multiple Myeloma
13
Lymphoma, Non-Hodgkin
13
Endometrial Neoplasms
13
Triple Negative Breast Neoplasms
12
Colonic Neoplasms
12
Carcinoma, Renal Cell
11
Stomach Neoplasms
10
Leukemia, Myeloid, Acute
10
Glioma
10
Gastrointestinal Neoplasms
10
Rectal Neoplasms
9
Lymphoma, Follicular
9
Lymphoma
9
Head and Neck Neoplasms
9
Small Cell Lung Carcinoma
8
Interventions
atezolizumab
2
Etoposide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Cancer Extensive Stage
×
30 days
×
Clear all
NCT05703971
2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2
Recruiting
62 enrolled
NCT07227597
2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled